{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:02Z","timestamp":1788716462096,"version":"build-2803163510"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1069,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1111\/j.1365-2133.2012.11162.x","type":"journal-article","created":{"date-parts":[[2012,7,21]],"date-time":"2012-07-21T03:07:36Z","timestamp":1342840056000},"page":"444-446","source":"Crossref","is-referenced-by-count":46,"title":["A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial"],"prefix":"10.1093","volume":"168","author":[{"given":"T.-F.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-Y.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,27]]},"reference":[{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB1|cit1","first-page":"300","article-title":"PHOENIX 1, PHOENIX 2, and ACCEPT study investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to 4\u2003years of follow-up","volume":"11","author":"Reich","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB4|cit4","unstructured":"Zheng M Zhu X Song M et\u00a0al. A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results"},{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB5|cit5","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","author":"Tsai","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB6|cit6","first-page":"553","article-title":"Clinical experience of QuantiFERON\u00ae-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan","volume":"164","author":"Chiu","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/40.3.341","article-title":"Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis","volume":"40","author":"Binymin","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2012.11162.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2012.11162.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2012.11162.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:56:49Z","timestamp":1676383009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/168\/2\/444\/6614396"}},"subtitle":["Correspondence"],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11162.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,27]]}}}